Literature DB >> 10416600

Castration-induced apoptosis of androgen-dependent shionogi carcinoma is associated with increased expression of genes encoding insulin-like growth factor-binding proteins.

T Nickerson1, H Miyake, M E Gleave, M Pollak.   

Abstract

Insulin-like growth factor (IGF)-I has well-characterized mitogenic and antiapoptotic effects that are essential for maintenance of the normal prostate and may be important during regression of the normal prostate and/or prostate tumors induced by androgen-targeting therapies for prostate cancer. IGF-I activity is modulated by IGF-binding proteins (IGFBPs). Here we examine IGFBP expression during regression of androgen-dependent Shionogi carcinoma tumors after castration. In this model, we observe a 90% reduction in Shionogi tumors by 10 days postcastration. Northern blotting of RNA from tumors collected at various times after castration indicates a rapid induction of IGFBP-5 concomitant with apoptotic regression of tumors, as detected by Apoptag staining of tumor sections after castration. IGFBP-5 mRNA was not detectable in tumors from control animals, but levels increased 120-fold in tumors 3 days after castration. The mRNAs for IGFBP-3 and 4 were abundant in Shionogi tumors from intact mice and decreased to -33% and -20% of control, respectively. Castration had no significant effect on IGFBP-2 expression. Treatment with calcium channel blockers inhibited castration-induced apoptosis and tumor regression and also significantly inhibited up-regulation of IGFBP-5 after castration. These data provide strong evidence for a functional role of IGFBP-5 expression in mediating the apoptosis induced by androgen deprivation in androgen-dependent neoplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10416600

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 2.  Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin Gleave; Hideaki Miyake
Journal:  World J Urol       Date:  2005-01-26       Impact factor: 4.226

3.  IGFBP-3 is a metastasis suppression gene in prostate cancer.

Authors:  Hemal H Mehta; Qinglei Gao; Colette Galet; Vladislava Paharkova; Junxiang Wan; Jonathan Said; Joanne J Sohn; Gregory Lawson; Pinchas Cohen; Laura J Cobb; Kuk-Wha Lee
Journal:  Cancer Res       Date:  2011-06-22       Impact factor: 12.701

Review 4.  Insulin-like growth factor system in cancer: novel targeted therapies.

Authors:  Varsha P Brahmkhatri; Chinmayi Prasanna; Hanudatta S Atreya
Journal:  Biomed Res Int       Date:  2015-03-19       Impact factor: 3.411

5.  Estrogen sensitivity of target genes and expression of nuclear receptor co-regulators in rat prostate after pre- and postnatal exposure to the ultraviolet filter 4-methylbenzylidene camphor.

Authors:  Stefan Durrer; Colin Ehnes; Michaela Fuetsch; Kirsten Maerkel; Margret Schlumpf; Walter Lichtensteiger
Journal:  Environ Health Perspect       Date:  2007-12       Impact factor: 9.031

6.  To die or to survive, a fatal question for the destiny of prostate cancer cells after androgen deprivation therapy.

Authors:  Kai-Xin Zhang; Jessica Firus; Brenda Prieur; William Jia; Paul S Rennie
Journal:  Cancers (Basel)       Date:  2011-03-24       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.